Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.
Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.
In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.
Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.
With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.
Cabenuva has received FDA approval for administration as few as six times a year for virologically suppressed adults with HIV-1, addressing treatment adherence challenges. This long-acting regimen combines cabotegravir and rilpivirine, initially approved in January 2021 for once-monthly dosing. The recent approval for every-two-month dosing was supported by the ATLAS-2M trial, showing comparable efficacy to monthly dosing. This innovation may significantly enhance patient experience and adherence, representing a noteworthy step forward in HIV treatment.
Pfizer and Ionis Pharmaceuticals announced the termination of the clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy aimed at cardiovascular risk reduction and severe hypertriglyceridemia. Despite meeting its primary endpoint of reducing non-HDL cholesterol and triglycerides in a Phase 2b study, the results were insufficient to justify further development. Additionally, vupanorsen was linked to dose-dependent liver fat increases and elevated liver enzymes. Pfizer will return development rights to Ionis, which licensed vupanorsen in November 2019.
Pfizer (NYSE: PFE) announced that the European Commission has approved LORVIQUA (lorlatinib) for treating adults with ALK-positive advanced non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor. This decision was based on the Phase 3 CROWN trial, demonstrating a 72% reduction in the risk of disease progression or death compared to XALKORI (crizotinib). The trial also reported a confirmed objective response rate of 76%, highlighting LORVIQUA's efficacy in patients with brain metastases.
Pfizer announced that the European Medicines Agency's CHMP has recommended conditional marketing authorization for PAXLOVID™ to treat COVID-19 in adults not requiring supplemental oxygen. If approved, it would be the first oral COVID-19 treatment recommended in the EU. The recommendation is based on clinical trial data showing PAXLOVID reduced the risk of hospitalization or death by 89% when administered within three days of symptom onset. Pfizer aims to produce up to 120 million treatment courses and is committed to equitable access worldwide.
Pfizer and BioNTech have commenced a clinical trial for an Omicron-based COVID-19 vaccine, evaluating safety and immunogenicity in 1,420 healthy adults aged 18-55. This study will assess various dosing regimens of the existing vaccine alongside the Omicron variant candidate. With the ongoing risk of waning vaccine effectiveness against emerging variants, the companies aim to provide longer-lasting protection. The trial is part of an extensive strategy to address evolving COVID-19 challenges while maintaining production capabilities of the current vaccine.
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) received a Complete Response Letter (CRL) from the FDA concerning their Biologics License Application for somatrogon, a once-weekly treatment for pediatric growth hormone deficiency (GHD). Pfizer will collaborate with the FDA to address the feedback. Despite the setback, somatrogon has gained approvals in several countries, including Japan, Canada, and Australia. The European Commission decision is expected soon. The companies remain committed to advancing somatrogon and addressing unmet medical needs in GHD.
Pfizer Inc. (NYSE: PFE) has received FDA approval for CIBINQO (abrocitinib), a once-daily oral JAK1 inhibitor aimed at adults with refractory, moderate-to-severe atopic dermatitis (AD). CIBINQO is indicated for those who do not respond to existing systemic therapies, including biologics. The approved doses are 50 mg, 100 mg, and 200 mg, with clinical trials involving over 1,600 patients demonstrating significant efficacy in skin clearance and itch relief. The product is expected to be available soon, marking a pivotal moment for patients struggling with this chronic condition.
Pfizer Inc. (NYSE:PFE) announced successful top-line results from a Phase 3 study evaluating the coadministration of PREVNAR 20™, a 20-valent pneumococcal conjugate vaccine, with the Pfizer-BioNTech COVID-19 Vaccine in adults aged 65 and older. The study included 570 participants and demonstrated similar immune responses whether administered together or individually. The safety profile was consistent with previous COVID-19 vaccine booster doses. Pfizer plans to publish detailed findings and is committed to promoting adult immunization amidst ongoing COVID-19 vaccinations.
Pfizer has entered a Development and Option agreement with Acuitas Therapeutics to license lipid nanoparticle (LNP) technology for up to 10 targets in vaccine or therapeutic development. This strategic collaboration enhances Pfizer's mRNA capabilities, building on the success of its COVID-19 vaccine, COMIRNATY®. Chief Scientific Officer Mikael Dolsten emphasized the goal of leveraging mRNA-LNP technology for breakthrough therapeutics. Acuitas, whose technology underpins COMIRNATY®, is also excited to support Pfizer in advancing new vaccine and therapeutic products.
Pfizer (PFE) and Beam Therapeutics (BEAM) announced a four-year research collaboration to develop in vivo base editing programs targeting rare genetic diseases. Beam will receive an upfront payment of
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
What is Pfizer Inc. known for?
Where is Pfizer's headquarters located?
How much does Pfizer make annually?
What are some of Pfizer's top-selling products?
What is the significance of Pfizer's international sales?
What recent collaborations has Pfizer been involved in?
When was Pfizer founded?
What is Pfizer's approach to innovation?
How does Pfizer contribute to cancer treatment?
What role do strategic partnerships play for Pfizer?
